[go: up one dir, main page]

TW200740429A - Methods and dosage forms for reducing side effects of carbamate compounds - Google Patents

Methods and dosage forms for reducing side effects of carbamate compounds

Info

Publication number
TW200740429A
TW200740429A TW095123239A TW95123239A TW200740429A TW 200740429 A TW200740429 A TW 200740429A TW 095123239 A TW095123239 A TW 095123239A TW 95123239 A TW95123239 A TW 95123239A TW 200740429 A TW200740429 A TW 200740429A
Authority
TW
Taiwan
Prior art keywords
methods
dosage forms
side effects
formula
reducing side
Prior art date
Application number
TW095123239A
Other languages
English (en)
Inventor
Richard G Weyers
Gayatri Sathyan
Ying Ou
Suneel K Gupta
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of TW200740429A publication Critical patent/TW200740429A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW095123239A 2005-06-29 2006-06-28 Methods and dosage forms for reducing side effects of carbamate compounds TW200740429A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69571505P 2005-06-29 2005-06-29

Publications (1)

Publication Number Publication Date
TW200740429A true TW200740429A (en) 2007-11-01

Family

ID=37310173

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095123239A TW200740429A (en) 2005-06-29 2006-06-28 Methods and dosage forms for reducing side effects of carbamate compounds

Country Status (7)

Country Link
US (1) US20070004797A1 (zh)
EP (1) EP1898885A1 (zh)
AR (1) AR054524A1 (zh)
CA (1) CA2613933A1 (zh)
PE (1) PE20070325A1 (zh)
TW (1) TW200740429A (zh)
WO (1) WO2007002906A1 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
ES2360102T3 (es) 2003-03-26 2011-05-31 Egalet A/S Sistema para la liberación controlada de morfina.
WO2006128471A2 (en) * 2005-06-03 2006-12-07 Egalet A/S A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection
EP2104493A2 (en) * 2007-01-16 2009-09-30 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
US20080292692A1 (en) * 2007-05-21 2008-11-27 Shira Pilch Impermeable Capsules
US8821928B2 (en) * 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
EP2187873B1 (en) * 2007-08-13 2018-07-25 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
WO2010083843A1 (en) * 2009-01-26 2010-07-29 Egalet A/S Controlled release formulations with continuous efficacy
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
WO2010088911A1 (en) * 2009-02-06 2010-08-12 Egalet A/S Pharmaceutical compositions resistant to abuse
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
EP2720686A4 (en) * 2011-06-15 2014-12-17 Orient Pharma Co Ltd MULTILAYER CAPSULE AND MANUFACTURING METHOD THEREFOR
AU2013285988A1 (en) 2012-07-06 2015-02-12 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
US20140275150A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
RU2294739C2 (ru) * 2001-02-27 2007-03-10 Орто-Макнейл Фармасьютикал, Инк. Производные карбамата для применения для предупреждения или лечения расстройств движений
CA2580640A1 (en) * 2004-09-16 2006-03-30 Janssen Pharmaceutica N.V. Methods of treating epileptogensis and epilepsy

Also Published As

Publication number Publication date
AR054524A1 (es) 2007-06-27
US20070004797A1 (en) 2007-01-04
EP1898885A1 (en) 2008-03-19
PE20070325A1 (es) 2007-05-12
CA2613933A1 (en) 2007-01-04
WO2007002906A1 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
TW200626068A (en) Active compounds for seed treatment
TW200740429A (en) Methods and dosage forms for reducing side effects of carbamate compounds
TW200738725A (en) Unsaturated mTOR inhibitors
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
MX2010004576A (es) Derivados de pirimidina novedosos.
MY151295A (en) Pyrimidyl indoline compound
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
TW200634018A (en) Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and uses
EA201170703A1 (ru) Производные адамантилбензамида
IL190730A0 (en) Potassium channel inhibitors
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
TW200738651A (en) Cyclohexyl sulfonamide derivatives
MX2007000224A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de nauseas y vomitos.
MX2008001428A (es) Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos.
TW200700071A (en) Novel use
MX2010001303A (es) Compuestos terapeuticos.
MY148651A (en) Antitumoral compounds
SG151306A1 (en) Novel benzothiazoles and the use thereof as medicaments
DE602008002598D1 (en) Cyclohexylderivate
TW200726763A (en) Novel compound
MY140538A (en) Substituted n-acyl-2-aminothiazoles
TW200738244A (en) 20-Alkyl, gemini vitamin D3 compounds and methods of use thereof
TNSN08242A1 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
TW200640376A (en) Reduction of digestibility of phosphorus